含曲妥珠单抗二线治疗HER2阳性乳腺癌的临床价值及安全性分析

Clinical Application of Second-Line Scheme Containing Trastuzumab in HER2-Positive Breast Cancer and Security Analysis

目的探讨含曲妥珠单抗二线治疗人表皮生长因子受体2(HER2)阳性乳腺癌的临床价值及安全性。方法选择采用二线方案治疗的78例HER2阳性乳腺癌患者为研究对象,根据患者治疗方式不同分为A组与B组。2组患者均接受吉西他滨联合卡培他滨二线治疗方案,B组患者同时接受曲妥珠单抗治疗。比较2组近期疗效、2年生存率及不良反应发生率。结果 A组与B组治疗有效率及临床获益率均无显著差异(P>0.05);B组2年生存率显著优于A组(P<0.05)。骨髓抑制及消化道不良反应是2组常见的化疗不良反应;曲妥珠单抗的主要不良反应为发热及疼痛,经对症治疗后均完成治疗。结论含曲妥珠单抗二线治疗方案治疗HER2阳性乳腺癌可延长患者生存期,安全性好。

Objective To explore the clinical application of second-line scheme containing trastuzumab in HER 2-posi-tive breast cancer and security analysis .Methods 78 cases of HER2-positive breast cancer who received second-line scheme were selected and divided into group A and group B according to treatment method .Both groups received second-line scheme con-taining gemcitabine and capecitabine .Group B were treated with trastuzumab therapy at the same time .Recent curative effects , survival rates and adverse reactions were compared between the 2 groups.Results There were no significant difference in effec-tive rate and clinical benefit rate between the 2 groups (P>0.05);2-year survival rate in group B was much higher than that of the group A(P <0.05);Myelosuppression and gastrointestinal reaction were the main chemotherapeutic side effect in the 2 groups;Fever and ache were the main adverse reactions of trastuzumab;All the patients completed the treatment after symptomatic treatment.Conclusion Second-line scheme containing trastuzumab for HER 2-positive breast cancer can prolong the survival time with good security .